Each step on the Adamas journey has been driven by our vision to make everyday life significantly better for people affected by neurological diseases
We expand our portfolio with the acquisition of a new medicine: OSMOLEX ER®, for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.
Adamas moving forward
We publish the final results of an open-label study (EASE LID 2) which demonstrate a sustained improvement in levodopa-induced dyskinesia among patients using GOCOVRI®.
We are issued a new patent for GOCOVRI that covers a method of reducing ‘OFF’ time and increasing ‘ON’ time without troublesome dyskinesia in people with Parkinson’s disease being treated with levodopa.
The FDA accepts for review our Supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease patients receiving levodopa-based therapy.
Neil McFarlane takes the reins of Adamas as CEO. GOCOVRI sales are $54.6 million for 2019.
GOCOVRI is approved and we launch
GOCOVRI is approved by the FDA in August 2017, our first sale is in November, and we launch commercially in January 2018. We build our national salesforce of neurology specialists.
Namzaric® launches and Adamas files NDA for GOCOVRI
Namzaric, our partnered drug with Forest Laboratories, a subsidiary of Allergan plc (now part of Abbvie), launches.
We file the NDA for GOCOVRI (ADS-5102).
Phase 3 study in Parkinson’s disease meets primary and secondary endpoints
Our Phase 3 GOCOVRI (ADS-5102) study in Parkinson’s disease meets its primary and key secondary endpoints. Our Phase 2/3 ADS-5102 study is published in Movement Disorders.
A successful IPO
Adamas conducts a successful Initial Public Offering (NASDAQ: ADMS).
Partnership to commercialize Namzaric®
Adamas and Forest Laboratories enter into an agreement to commercialize Namzaric, a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
Phase 2/3 study focuses on dyskinesia and OFF
Our Phase 2/3 GOCOVRI (ADS-5102) study focuses on dyskinesia and OFF time in patients with Parkinson’s disease, meeting its primary endpoint in 2013.
First Phase 1 clinical studies; we become Adamas
We conduct our initial Phase 1 trials, leading to Namzaric® (ADS-8704) and GOCOVRI® (ADS-5102).
We become Adamas Pharmaceuticals in July 2007.
Opening in Emeryville
NeuroMolecular moves into offices in Emeryville, CA.
Putting patients first right from the start
Adamas is originally founded as NeuroMolecular, Inc., by Gregory Went, PhD, co-founder of the pioneering genomics firm CuraGen, and several scientific advisors. He was later joined by key members who helped build the platform and guide the portfolio, including Ivan Lieberburg, MD, PhD, from Athena Neurosciences and Elan, and Efraim Shek, PhD, from Syntex, Cephalon, and Abbott.